Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Combinatorial Pharmacogenetic Interactions of Bucindolol and β1, α2C Adrenergic Receptor Polymorphisms

10 Oct 2012

Abstract excerpt

BACKGROUND: Pharmacogenetics involves complex interactions of gene products affecting pharmacodynamics and pharmacokinetics, but there is little information on the interaction of multiple genetic modifiers of drug response. Bucindolol is a β-blocker/sympatholytic agent whose efficacy is modulated by polymorphisms in the primary target (β(1) adrenergic receptor [AR] Arg389 Gly on cardiac myocytes) and a secondary...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cardiac electrophysiology and arrhythmias
Share to Pharmacogenetics and Drug Metabolism
Share to Receptor Mechanisms and Signaling

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 23071495
DOI: 10.1371/journal.pone.0044324

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Combinatorial Pharmacogenetic Interactions of Bucindolol and β1, α2C Adrenergic Receptor PolymorphismsPMID 23071495Read ↗

Pharmacogenomics of Bucindolol in Atrial Fibrillation and Heart Failure.Semantic proximity Read ↗

A polymorphism within a conserved beta(1)-adrenergic receptor motif alters cardiac function and beta-blocker response in human heart failure.Semantic proximity Read ↗

Synergistic polymorphisms of beta1- and alpha2C-adrenergic receptors and the risk of congestive heart failure.Semantic proximity Read ↗

Cardiovascular pharmacogenomics of adrenergic receptor signaling: clinical implications and future directions.Semantic proximity Read ↗

Mechanisms of pharmacogenomic effects of genetic variation within the cardiac adrenergic network in heart failure.Semantic proximity Read ↗

β<sub>1</sub>- and β<sub>2</sub>-adrenergic Receptor Haplotypes Regulate Therapeutic Responses to Placebo and the Biased Ligand β-blocker BucindololSemantic proximity Read ↗

Pharmacogenomics of β-adrenergic receptor physiology and response to β-blockade.Semantic proximity Read ↗

Mechanisms of Disease: β-adrenergic receptors—alterations in signal transduction and pharmacogenomics in heart failureSemantic proximity Read ↗

Pharmacogenetics of Beta-1- and Beta-2-Adrenergic ReceptorsSemantic proximity Read ↗

Polymorphisms of cardiac presynaptic alpha2C adrenergic receptors: Diverse intragenic variability with haplotype-specific functional effects.Semantic proximity Read ↗

A genotype-directed comparative effectiveness trial of Bucindolol and metoprolol succinate for prevention of symptomatic atrial fibrillation/atrial flutter in patients with heart failure: Rationale and design of the GENETIC-AF trial.Semantic proximity Read ↗

Bucindolol Decreases Atrial Fibrillation Burden in Patients With Heart Failure and the ADRB1 Arg389Arg Genotype.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.